Deoxymab 3E10 is the world’s first cell-penetrating anti-DNA antibody for the potential treatment of
cancer and has the prospect of revolutionising treatment across a broad range of cancers
Ann: Chairman's Address and CEO Presentation to 2019 AGM, page-3
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 154511 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 4813825 | 5 |
View Market Depth
| Last trade - 16.12pm 31/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable